132 related articles for article (PubMed ID: 35911441)
1. Molecular Landscape of
Wang H; Miao J; Wen Y; Xia X; Chen Y; Huang M; Chen S; Zhao Z; Zhang Y; Chen C; Zhu X
Pathol Oncol Res; 2022; 28():1610360. PubMed ID: 35911441
[No Abstract] [Full Text] [Related]
2. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
3. Detection of
Lee J; Franovic A; Shiotsu Y; Kim ST; Kim KM; Banks KC; Raymond VM; Lanman RB
Front Oncol; 2019; 9():212. PubMed ID: 31019892
[No Abstract] [Full Text] [Related]
4. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
5. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
Ross JS; Wang K; Gay LM; Al-Rohil RN; Nazeer T; Sheehan CE; Jennings TA; Otto GA; Donahue A; He J; Palmer G; Ali S; Nahas M; Young G; Labrecque E; Frampton G; Erlich R; Curran JA; Brennan K; Downing SR; Yelensky R; Lipson D; Hawryluk M; Miller VA; Stephens PJ
Clin Cancer Res; 2014 Jan; 20(1):68-75. PubMed ID: 24192927
[TBL] [Abstract][Full Text] [Related]
6. Emergence of
Subramanian J; Katta A; Masood A; Vudem DR; Kancha RK
Oncologist; 2019 Dec; 24(12):e1303-e1314. PubMed ID: 31292270
[TBL] [Abstract][Full Text] [Related]
7. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H
Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184
[TBL] [Abstract][Full Text] [Related]
8. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
[TBL] [Abstract][Full Text] [Related]
9. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
10. Targeting ERBB2 mutations in solid tumors: biological and clinical implications.
Cousin S; Khalifa E; Crombe A; Laizet Y; Lucchesi C; Toulmonde M; Le Moulec S; Auzanneau C; Soubeyran I; Italiano A
J Hematol Oncol; 2018 Jun; 11(1):86. PubMed ID: 29941010
[TBL] [Abstract][Full Text] [Related]
11. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.
Wen W; Chen WS; Xiao N; Bender R; Ghazalpour A; Tan Z; Swensen J; Millis SZ; Basu G; Gatalica Z; Press MF
J Mol Diagn; 2015 Sep; 17(5):487-95. PubMed ID: 26320869
[TBL] [Abstract][Full Text] [Related]
13. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.
Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M
Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883
[TBL] [Abstract][Full Text] [Related]
14. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
15. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.
Laforest A; Aparicio T; Zaanan A; Silva FP; Didelot A; Desbeaux A; Le Corre D; Benhaim L; Pallier K; Aust D; Pistorius S; Blons H; Svrcek M; Laurent-Puig P
Eur J Cancer; 2014 Jul; 50(10):1740-1746. PubMed ID: 24797764
[TBL] [Abstract][Full Text] [Related]
16. Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.
Madison RW; Gupta SV; Elamin YY; Lin DI; Pal SK; Necchi A; Miller VA; Ross JS; Chung JH; Alexander BM; Schrock AB; Heymach JV; Reddy P; Ali SM
BJU Int; 2020 May; 125(5):739-746. PubMed ID: 31985116
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.
Cabel L; Fuerea A; Lacroix L; Baldini C; Martin P; Hollebecque A; Postel-Vinay S; Varga A; Balheda R; Gazzah A; Michot JM; Marabelle A; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; Scoazec JY; Ammari S; André F; Soria JC; Massard C; Verlingue L
Oncotarget; 2018 Feb; 9(11):9741-9750. PubMed ID: 29515767
[TBL] [Abstract][Full Text] [Related]
18. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
Kim ST; Banks KC; Pectasides E; Kim SY; Kim K; Lanman RB; Talasaz A; An J; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Park SH; Park JO; Park YS; Lim HY; Kim NKD; Park W; Lee H; Bass AJ; Kim K; Kang WK; Lee J
Ann Oncol; 2018 Apr; 29(4):1037-1048. PubMed ID: 29409051
[TBL] [Abstract][Full Text] [Related]
19. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
Nakamura K; Aimono E; Oba J; Hayashi H; Tanishima S; Hayashida T; Chiyoda T; Kosaka T; Hishida T; Kawakubo H; Kitago M; Okabayashi K; Funakoshi T; Okita H; Ikeda S; Takaishi H; Nishihara H
Med Oncol; 2021 Mar; 38(4):36. PubMed ID: 33710417
[TBL] [Abstract][Full Text] [Related]
20. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
